乳房刺激与低剂量缩宫素用于一次剖宫产史产妇引产加强的随机对照试验
这项单中心随机对照试验纳入33例乳房刺激组和34例静脉低剂量缩宫素组的一次剖宫产史产妇,比较引产加强效果。乳房刺激组从加强到分娩的中位时间更长(10.9小时 vs 5.1小时,P<.001),但宫缩过频率更低(6% vs 27%,P=.044),两组24小时内分娩率及新生儿结局相似。
要点
- 乳房刺激组从加强到分娩的中位时间长于缩宫素组(10.9小时 vs 5.1小时,P<.001)。
- 乳房刺激组宫缩过频率低于缩宫素组(6% vs 27%,P=.044),但宫缩过频相关胎心不可靠发生率无显著差异(6% vs 21%,P=.427)。
- 两组阴道分娩率、24小时内分娩率及新生儿结局相似,缩宫素组2例(5.6%)发生子宫破裂,乳房刺激组0例(P=.492)。
核心结论
- 在有一次剖宫产史的产妇中,与静脉缩宫素相比,乳房刺激有效,阴道分娩率和24小时内分娩率相似,宫缩过频更少。
- 需要更大规模的随机对照试验来确认乳房刺激加强引产的安全性。
研究设计与样本
- 随机对照试验,在单家三级大学附属医院开展。
- 纳入有一次剖宫产史、宫颈扩张2至6厘米、宫缩不足(每10分钟少于3次)且适合引产加强的产妇。
- 随机分为乳房刺激组(使用吸乳器)33例和静脉低剂量缩宫素组34例,缩宫素起始0.5至2毫单位/分,每15至40分钟增加1至2毫单位/分。
- 两组均放置宫内压力导管,加强治疗最长持续12小时,若12小时内未进入活跃期则判定干预失败,采用意向性分析。
主要发现
- 乳房刺激组从加强到分娩的中位时间长于缩宫素组:10.9小时(总范围1.5-63.2)vs 5.1小时(0.8-30),P<.001。
- 第一产程宫缩强度(蒙得维的亚单位)两组相似:125(70-270)vs 180(80-280),P=.110;第二产程:145(30-280)vs 175(50-290),P=.164。
- 乳房刺激组宫缩过频率低于缩宫素组:6% vs 27%,P=.044;宫缩过频相关胎心不可靠发生率无显著差异:6% vs 21%,P=.427。
- 两组24小时内分娩比例相似;缩宫素组2例(5.6%)发生子宫破裂,乳房刺激组0例,P=.492。
- 两组分娩途径和新生儿结局相似。
局限性
- 需要更大规模的随机对照试验来确认乳房刺激加强引产的安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oxytocin and breast stimulation are methods used for labor augmentation in women with a previous cesarean delivery (CD). Compared to spontaneous labor, labor augmentation has been shown to increase the risk of uterine rupture in women with a previous CD. The optimal method of labor augmentation for women with a prior CD has not been established. OBJECTIVE: In a cohort of patients with one previous CD, we aimed to compare maternal and neonatal outcomes according to the method of labor augmentation; breast stimulation or intravenous oxytocin. STUDY DESIGN: This randomized controlled trial (RCT) was conducted at a single, tertiary, university-affiliated hospital. The participants had one previous CD and a cervical dilatation of 2 to 6 cm, had inadequate uterine contractions, defined as less than 3 per 10 minutes, and were candidates for labor augmentation. They were randomized for augmentation by breast stimulation using a breast pump, or by intravenous low-dose oxytocin starting at 0.5 to 2 milliunits/min and increasing incrementally by 1 to 2 milliunits/min every 15 to 40 minutes. An intrauterine pressure catheter was inserted. Both augmentation treatments were continued for a maximum of 12 hours. If active labor did not occur within 12 hours, the intervention was deemed a failure. An intention-to-treat analysis was performed. The co-primary outcomes were the time from augmentation to delivery, and uterine contraction intensity as measured by Montevideo units (MVU). Secondary outcomes included intervention failure, meconium-stained amniotic fluid, vaginal delivery after cesarean section, uterine rupture, infectious outcomes, postpartum hemorrhage, and maternal hospitalization length. The neonatal outcomes included: Apgar score at 5 minutes, umbilical cord pH<7.1, neonatal intensive care unit admission, asphyxia, and perinatal death. RESULTS: The breast stimulation and the intravenous oxytocin groups included 33 and 34 patients, respectively. The participants' demographic and obstetric characteristics were similar. The median time from augmentation to delivery was longer in the breast stimulation than the oxytocin group: 10.9 hours (total range 1.5-63.2) vs 5.1 hours (0.8-30), P<.001. The median (range) contraction intensity as measured by MVU was similar between the groups in the first stage of labor, 125 (70-270) vs 180 (80-280), P=.110; and in the second stage of labor, 145 (30-280), vs 175 (50-290), P=.164. The tachysystole rate was lower, with statistical significance, in the breast stimulation than the oxytocin group, 6% vs 27%, P=.044; while the rates of tachysystole-associated nonreassuring fetal heart rates did not differ significantly, 6% vs 21%, P=.427. Similar proportions of patients delivered within 24 hours of intervention. Uterine rupture occurred in two patients in the oxytocin group (5.6%) and in none in the breast stimulation group, P=.492. The delivery route and neonatal outcomes were similar between the groups. CONCLUSION: We showed that among patients with one previous CD, breast stimulation compared to intravenous oxytocin was effective, with similar vaginal delivery rates and deliveries within 24 hours, and less frequent tachysystole. A larger RCT is needed to confirm the safety of augmentation by breast stimulation. El resumen está disponible en Español al final del artículo.
引用
- Abu Shqara R, Goldinfeld G, Assulyn T, et al. Breast stimulation vs low dose oxytocin for labor augmentation in women with a previous cesarean delivery, a randomized controlled trial. Am J Obstet Gynecol MFM. 2025. PMID: 40054666. doi:10.1016/j.ajogmf.2025.101658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。